NBTX
Income statement / Annual
Last year (2023), Nanobiotix S.A.'s total revenue was $30.06 M,
an increase of 529.36% from the previous year.
In 2023, Nanobiotix S.A.'s net income was -$39.70 M.
See Nanobiotix S.A.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$30.06 M
|
$4.78 M
|
$10,000.00
|
$50,000.00
|
$68,000.00
|
$116,000.00
|
$251,968.00
|
$1.56 M
|
$265,543.00
|
$967,500.00
|
| Cost of Revenue |
$0.00 |
$985,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$345,591.00 |
$436,307.00 |
$359,611.00 |
$0.00 |
| Gross Profit |
$30.06 M |
$3.79 M |
$10,000.00 |
$50,000.00 |
$68,000.00 |
$116,000.00 |
-$93,623.00 |
$1.12 M |
-$94,068.00 |
$967,500.00 |
| Gross Profit Ratio |
1 |
0.79 |
1 |
1 |
1 |
1 |
-0.37 |
0.72 |
-0.35 |
1 |
| Research and Development
Expenses |
$38.40 M
|
$32.64 M
|
$30.38 M
|
$24.33 M
|
$30.41 M
|
$20.89 M
|
$16.34 M
|
$16.92 M
|
$13.90 M
|
$8.08 M
|
| General & Administrative
Expenses |
$21.66 M
|
$17.48 M
|
$19.43 M
|
$14.27 M
|
$18.64 M
|
$12.62 M
|
$12.34 M
|
$10.26 M
|
$7.19 M
|
$4.30 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$21.66 M
|
$17.48 M
|
$19.43 M
|
$14.27 M
|
$18.64 M
|
$12.62 M
|
$12.34 M
|
$10.26 M
|
$7.19 M
|
$4.30 M
|
| Other Expenses |
-$3.22 M |
-$3.41 M |
-$2.64 M |
-$2.07 M |
-$2.20 M |
-$3.33 M |
-$337,890.00 |
$160,230.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$56.84 M |
$46.70 M |
$47.18 M |
$36.53 M |
$46.85 M |
$30.18 M |
$25.52 M |
$23.41 M |
$17.41 M |
$10.59 M |
| Cost And Expenses |
$56.84 M |
$46.70 M |
$47.18 M |
$36.53 M |
$46.85 M |
$30.18 M |
$25.52 M |
$23.41 M |
$17.41 M |
$10.59 M |
| Interest Income |
$1.22 M |
$256,000.00 |
$6.17 M |
$4.68 M |
$105,000.00 |
$34,000.00 |
$33,026.00 |
$59,492.00 |
$183,218.00 |
$196,648.00 |
| Interest Expense |
$7.98 M |
$5.84 M |
$590,000.00 |
$333,000.00 |
$4.79 M |
$847,000.00 |
$108,367.00 |
$102,203.00 |
$59,517.00 |
$55,726.00 |
| Depreciation &
Amortization |
$1.51 M
|
$1.50 M
|
$1.56 M
|
$1.76 M
|
$1.77 M
|
$569,000.00
|
$345,591.00
|
$436,307.00
|
$456,080.00
|
$307,560.00
|
| EBITDA |
-$30.09 M
|
-$45.15 M
|
-$45.61 M
|
-$31.49 M
|
-$44.78 M
|
-$29.33 M
|
-$25.55 M
|
-$21.21 M
|
-$16.49 M
|
-$9.11 M
|
| EBITDA Ratio |
-1 |
-10.85 |
-4099.5 |
-599.06 |
-658.46 |
-252.83 |
-101.72 |
-13.61 |
-62.09 |
-9.42 |
| Operating Income Ratio
|
-0.89
|
-9.78
|
-5257.9
|
-728.56
|
-687.93
|
-259.2
|
-100.28
|
-14.03
|
-64.55
|
-9.94
|
| Total Other
Income/Expenses Net |
-$12.80 M
|
-$10.33 M
|
$5.58 M
|
$2.85 M
|
-$4.13 M
|
-$278,000.00
|
-$876,000.00
|
$64,607.00
|
$138,563.00
|
$142,523.00
|
| Income Before Tax |
-$39.58 M |
-$57.03 M |
-$47.00 M |
-$33.61 M |
-$50.91 M |
-$30.35 M |
-$26.14 M |
-$21.79 M |
-$17.00 M |
-$9.48 M |
| Income Before Tax Ratio
|
-1.32
|
-11.94
|
-4699.9
|
-672.28
|
-748.71
|
-261.59
|
-103.76
|
-13.99
|
-64.03
|
-9.8
|
| Income Tax Expense |
$120,000.00 |
$10,000.00 |
$5,000.00 |
$9,000.00 |
$3,000.00 |
-$449,000.00 |
$20.00 |
$90,425.00 |
$37,578.00 |
$79,271.00 |
| Net Income |
-$39.70 M |
-$57.04 M |
-$47.00 M |
-$33.62 M |
-$50.92 M |
-$29.90 M |
-$26.14 M |
-$21.88 M |
-$17.00 M |
-$9.56 M |
| Net Income Ratio |
-1.32 |
-11.94 |
-4700.4 |
-672.46 |
-748.75 |
-257.72 |
-103.76 |
-14.04 |
-64.03 |
-9.88 |
| EPS |
-1.08 |
-1.64 |
-1.35 |
-1.38 |
-2.35 |
-1.52 |
-1.5 |
-1.43 |
-1.2 |
-0.74 |
| EPS Diluted |
-1.08 |
-1.64 |
-1.35 |
-1.38 |
-2.35 |
-1.52 |
-1.5 |
-1.43 |
-1.2 |
-0.74 |
| Weighted Average Shares
Out |
$36.93 M
|
$34.85 M
|
$34.73 M
|
$24.39 M
|
$21.63 M
|
$19.62 M
|
$17.43 M
|
$15.28 M
|
$14.14 M
|
$12.87 M
|
| Weighted Average Shares
Out Diluted |
$36.93 M
|
$34.85 M
|
$34.73 M
|
$24.39 M
|
$21.63 M
|
$19.63 M
|
$17.48 M
|
$15.28 M
|
$14.14 M
|
$12.87 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
